RxDoctor Payments Data

Bradley Hamrick, MD

Internal Medicine · Danville, INNPI 1235117987

Payments from drug & device makers

$741in general payments, 2019–2025

Across 43 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$142
  • Pfizer$132
  • GSK$107
  • Lilly USA, LLC$82
  • Abbott$54
  • AstraZeneca$53
  • plus $173 from 8 others

What the payments were for

  • Food & beverage$741100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$741 in reported general payments places this provider in the 70th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$190,852
Medicare patients
301
Services billed
10,041

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin122$185,028
EliquisApixaban77$96,198
JanuviaSitagliptin Phosphate35$44,785
OzempicSemaglutide23$37,590
Bydureon BciseExenatide Microspheres18$36,390
RybelsusSemaglutide13$34,194
XareltoRivaroxaban20$32,424
Spiriva HandihalerTiotropium Bromide15$23,417
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$22,313
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$15,960
Tresiba Flextouch U-100Insulin Degludec21$14,748
Potassium Chloride308$12,186
MounjaroTirzepatide12$11,780
Atorvastatin Calcium877$8,213
Ezetimibe306$7,850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$29$185,028122 claims
PfizerEliquis$132$96,19877 claims
Novo NordiskOzempic, Rybelsus$142$71,78436 claims
GSKTrelegy Ellipta, Anoro Ellipta$107$29,50824 claims
Lilly USA, LLCMounjaro$82$11,78012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Danville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →